Jeffrey D Milbrandt

Washington University

$49,168,006

Attributed

$77,180,808

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $17M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$77,180,808 · 26

By mechanism

R01$35,608,587 · 12

UM1$28,031,931 · 1

P50$2,989,521 · 1

U19$2,916,525 · 2

RF1$2,820,477 · 1

R21$1,977,877 · 5

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Pathway Interactions”

David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
David R. Weir · University Of Michigan At Ann Arbor$129,316,139
Daniel Ernest Ford · Johns Hopkins University$108,075,637
David W Simpson · University Of Southern California$88,046,235
Charles D. Blanke · Oregon Health And Science University$86,571,896

Research focus

Pathway InteractionsNeuronsMolecularAxonMutationCellsProgramsProteinsAxonal DegenerationGenesResponseGeneticMediatingLinkInjuryAffectExperimental StudyPeripheral Nervous System DiseasesLeadPhenotypeMetabolicIn VivoEnzymesNeurodegenerative Disorders

Grant awards (114)

Connecting Rare Mutations to Common Pathways$1,164,521

P50 · FY2025 · HD · contact PI

Multi-omics peripheral nerve atlas enables fine-mapping of pain molecular phenotypes$727,766

U19 · FY2025 · NS · contact PI

Compromised LDH activity causes motor deficits and hastens ALS progression$635,296

R01 · FY2025 · AG · contact PI

Dissection of SARM1-Induced Axon Degeneration and Cell Death$603,990

R01 · FY2025 · NS · contact PI

The role of SARM1 in neuroinflammation-mediated axonal damage$550,543

R01 · FY2025 · NS · contact PI

SARM1 functional polymorphisms and their contribution to ALS risk$537,074

R01 · FY2025 · NS

Connecting Rare Mutations to Common Pathways$250,000

P50 · FY2025 · HD · contact PI

Multi-omics peripheral nerve atlas enables fine-mapping of pain molecular phenotypes$727,766

U19 · FY2024 · NS · contact PI

Compromised LDH activity causes motor deficits and hastens ALS progression$648,261

R01 · FY2024 · AG · contact PI

SARM1 functional polymorphisms and their contribution to ALS risk$578,847

R01 · FY2024 · NS

Dissection of SARM1-Induced Axon Degeneration and Cell Death$566,796

R01 · FY2024 · NS · contact PI

The role of SARM1 in neuroinflammation-mediated axonal damage$532,505

R01 · FY2024 · NS · contact PI

Connecting Rare Mutations to Common Pathways$315,000

P50 · FY2024 · HD · contact PI

Multi-omics peripheral nerve atlas enables fine-mapping of pain molecular phenotypes$727,766

U19 · FY2023 · NS · contact PI

SARM1 functional polymorphisms and their contribution to ALS risk$620,137

R01 · FY2023 · NS

Dissection of SARM1-Induced Axon Degeneration and Cell Death$598,620

R01 · FY2023 · NS · contact PI

Compromised LDH activity causes motor deficits and hastens ALS progression$521,755

R01 · FY2023 · AG · contact PI

Connecting Rare Mutations to Common Pathways$315,000

P50 · FY2023 · HD · contact PI

Genome Engineering & iPSC Center Core$153,544

P01 · FY2023 · DK · contact PI

Multi-omics peripheral nerve atlas enables fine-mapping of pain molecular phenotypes$733,227

U19 · FY2022 · NS · contact PI

SARM1 functional polymorphisms and their contribution to ALS risk$620,137

R01 · FY2022 · NS

Dissection of SARM1-Induced Axon Degeneration and Cell Death$598,620

R01 · FY2022 · NS · contact PI

Compromised LDH activity causes motor deficits and hastens ALS progression$503,248

R56 · FY2022 · AG · contact PI

Connecting Rare Mutations to Common Pathways$315,000

P50 · FY2022 · HD · contact PI

Genome Engineering & iPSC Center Core$154,577

P01 · FY2022 · DK · contact PI

Dissection of SARM1-Induced Axon Degeneration and Cell Death$598,620

R01 · FY2021 · NS · contact PI

SARM1 functional polymorphisms and their contribution to ALS risk$512,555

R01 · FY2021 · NS

(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy$465,400

R01 · FY2021 · CA

Jun O-GlcNAcylation Regulates Schwann Cell Injury Response$411,521

R01 · FY2021 · NS · contact PI

Connecting Rare Mutations to Common Pathways$315,000

P50 · FY2021 · HD · contact PI

Genome Engineering & iPSC Center Core$155,580

P01 · FY2021 · DK · contact PI

A Platform for Large-Scale Discovery in Common Disease$13,031,931

UM1 · FY2020 · HG

Dissection of SARM1-Induced Axon Degeneration and Cell Death$552,223

R01 · FY2020 · NS · contact PI

(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy$465,400

R01 · FY2020 · CA

Jun O-GlcNAcylation Regulates Schwann Cell Injury Response$411,521

R01 · FY2020 · NS · contact PI

Connecting Rare Mutations to Common Pathways$315,000

P50 · FY2020 · HD · contact PI

Genome Engineering & iPSC Center Core$156,125

P01 · FY2020 · DK · contact PI

A Platform for Large-Scale Discovery in Common Disease$15,000,000

UM1 · FY2019 · HG

Dissection of SARM1-Induced Axon Degeneration and Cell Death$508,832

R01 · FY2019 · NS · contact PI

Identifying inhibitors of axon degeneration for the treatment of TIPN$495,082

R01 · FY2019 · CA · contact PI

(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy$451,437

R01 · FY2019 · CA

Jun O-GlcNAcylation Regulates Schwann Cell Injury Response$399,768

R01 · FY2019 · NS · contact PI

Genome Engineering & iPSC Center Core$161,750

P01 · FY2019 · DK · contact PI

Identifying inhibitors of axon degeneration for the treatment of TIPN$510,845

R01 · FY2018 · CA · contact PI

(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy$465,400

R01 · FY2018 · CA

Jun O-GlcNAcylation Regulates Schwann Cell Injury Response$399,768

R01 · FY2018 · NS · contact PI

DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATH$364,634

R01 · FY2018 · NS · contact PI

Regulating NAD Metabolism to Inhibit Axon Degeneration in Neurodegenerative Diseases$2,820,477

RF1 · FY2017 · AG · contact PI

A HIGH-THROUGHPUT ASSAY FOR PRECONDITIONING FACTORS THAT PROMOTE AXONAL REGENERAT$534,265

R33 · FY2017 · NS

Metabolic Regulation of the Schwann Cell Injury Response$477,285

R56 · FY2017 · NS · contact PI

(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy$445,407

R01 · FY2017 · CA

Identifying inhibitors of axon degeneration for the treatment of TIPN$438,262

R01 · FY2017 · CA · contact PI

DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATH$364,634

R01 · FY2017 · NS · contact PI

A HIGH-THROUGHPUT ASSAY FOR PRECONDITIONING FACTORS THAT PROMOTE AXONAL REGENERAT$539,516

R33 · FY2016 · NS

DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATH$364,634

R01 · FY2016 · NS · contact PI

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS$353,314

R01 · FY2016 · AG · contact PI

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS$505,321

R01 · FY2015 · AG · contact PI

DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATH$364,634

R01 · FY2015 · NS · contact PI

MOLECULAR CHARACTERIZATION OF NON-MYELINATING SCHWANN CELLS$258,280

R21 · FY2015 · NS · contact PI

USING CAS9 ATFS TO ALTER TRANSCRIPTION NETWORKS AND CONVERT FIBROBLASTS TO GLIA$228,750

R21 · FY2015 · NS

A HIGH-THROUGHPUT ASSAY FOR PRECONDITIONING FACTORS THAT PROMOTE AXONAL REGENERAT$209,000

R21 · FY2015 · NS

IDENTIFICATION OF AXONAL DEGENERATION PATHWAYS$616,200

R01 · FY2014 · NS

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS$516,992

R01 · FY2014 · AG · contact PI

DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATH$352,052

R01 · FY2014 · NS · contact PI

MOLECULAR CHARACTERIZATION OF NON-MYELINATING SCHWANN CELLS$296,162

R21 · FY2014 · NS · contact PI

A HIGH-THROUGHPUT ASSAY FOR PRECONDITIONING FACTORS THAT PROMOTE AXONAL REGENERAT$209,000

R21 · FY2014 · NS

USING CAS9 ATFS TO ALTER TRANSCRIPTION NETWORKS AND CONVERT FIBROBLASTS TO GLIA$190,625

R21 · FY2014 · NS

IDENTIFICATION OF AXONAL DEGENERATION PATHWAYS$593,782

R01 · FY2013 · NS

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS$488,558

R01 · FY2013 · AG · contact PI

IDENTIFICATION OF AXONAL DEGENERATION PATHWAYS$635,834

R01 · FY2012 · NS

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS$516,992

R01 · FY2012 · AG · contact PI

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS$516,990

R01 · FY2011 · AG · contact PI

IDENTIFYING THE NMNAT AXON PROTECTION PATHWAY VIA MULTIPLE SCREENING PARADIGMS$219,154

R21 · FY2011 · NS · contact PI

Physiology and Genetics of GDNF Family of Ligands (GFLS)$574,148

R01 · FY2010 · AG · contact PI

IDENTIFYING THE NMNAT AXON PROTECTION PATHWAY VIA MULTIPLE SCREENING PARADIGMS$190,000

R21 · FY2010 · NS · contact PI

Physiology and Genetics of GDNF Family of Ligands (GFLS)$563,052

R01 · FY2009 · AG · contact PI

Regulation of Myelination by Egr2/Nab Protein Complexes$368,980

R01 · FY2009 · NS · contact PI

Loss of Nkx3.1-an Initiating Event in Prostate Cancer$284,645

R01 · FY2009 · CA · contact PI

Regulation of Myelination by Egr2/Nab Protein Complexes$76,141

R01 · FY2009 · NS · contact PI

Regulation of Myelination by Egr2/Nab Protein Complexes$29,517

R01 · FY2009 · NS · contact PI

Physiology and Genetics of GDNF Family of Ligands (GFLS)$546,654

R01 · FY2008 · AG · contact PI

Regulation of Myelination by Egr2/Nab Protein Complexes$368,980

R01 · FY2008 · NS · contact PI

Specificity of RET signaling: physiology and regulation$335,479

R01 · FY2008 · NS · contact PI

Loss of Nkx3.1-an Initiating Event in Prostate Cancer$284,645

R01 · FY2008 · CA · contact PI

Physiology and Genetics of GDNF Family of Ligands (GFLS)$541,564

R01 · FY2007 · AG · contact PI

Regulation of Myelination by Egr2/Nab Protein Complexes$369,486

R01 · FY2007 · NS · contact PI

Specificity of RET signaling: physiology and regulation$335,479

R01 · FY2007 · NS · contact PI

Loss of Nkx3.1-an Initiating Event in Prostate Cancer$284,800

R01 · FY2007 · CA · contact PI

Physiology and Genetics of GDNF Family of Ligands (GFLS)$543,272

R01 · FY2006 · AG · contact PI

Specificity of RET signaling: physiology and regulation$345,498

R01 · FY2006 · NS · contact PI

Loss of Nkx3.1-an Initiating Event in Prostate Cancer$294,270

R01 · FY2006 · CA · contact PI

Regulation of Myelination by Egr2/Nab Protein Complexes$228,604

R01 · FY2006 · NS · contact PI

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS (GFLS)$438,312

R01 · FY2005 · AG

ROLE OF EGR2 MUTATIONS IN PERIPHERAL MYELINOPATHIES$385,000

R01 · FY2005 · NS

Specificity of RET signaling: physiology and regulation$353,813

R01 · FY2005 · NS

Loss of Nkx3.1-an Initiating Event in Prostate Cancer$271,958

R01 · FY2005 · CA

Novel E3 Ligases in Nerve Degeneration and Regeneration$176,906

R21 · FY2005 · NS

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS (GFLS)$427,635

R01 · FY2004 · AG

ROLE OF EGR2 MUTATIONS IN PERIPHERAL MYELINOPATHIES$385,000

R01 · FY2004 · NS

Specificity of RET signaling: physiology and regulation$353,813

R01 · FY2004 · NS

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS (GFLS)$417,268

R01 · FY2003 · AG

ROLE OF EGR2 MUTATIONS IN PERIPHERAL MYELINOPATHIES$385,000

R01 · FY2003 · NS

GFRA RECEPTOR LIGAND INTERACTION AND BIOLOGICAL ROLES$352,127

R01 · FY2003 · NS

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS (GFLS)$407,158

R01 · FY2002 · AG

ROLE OF EGR2 MUTATIONS IN PERIPHERAL MYELINOPATHIES$346,500

R01 · FY2002 · NS

GFRA RECEPTOR LIGAND INTERACTION AND BIOLOGICAL ROLES$343,343

R01 · FY2002 · NS

ROLE OF NKX3.1 IN PROSTATE DEVELOPMENT AND CANCER$334,201

R01 · FY2002 · CA

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS (GFLS)$396,779

R01 · FY2001 · AG

ROLE OF EGR2 MUTATIONS IN PERIPHERAL MYELINOPATHIES$347,156

R01 · FY2001 · NS

GFRA RECEPTOR LIGAND INTERACTION AND BIOLOGICAL ROLES$335,267

R01 · FY2001 · NS

NKX31 AND PROSTATE DEVELOPMENT AND CANCER$302,078

R01 · FY2001 · CA

PHYSIOLOGY AND GENETICS OF THE GDNF HOMOLOG NEURTURIN$375,238

R01 · FY2000 · AG

GFRA RECEPTOR LIGAND INTERACTION AND BIOLOGICAL ROLES$328,921

R01 · FY2000 · NS

NKX31 AND PROSTATE DEVELOPMENT AND CANCER$247,613

R01 · FY2000 · CA